Invivyd, Inc. (IVVD)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. William E. Duke Jr., M.B.A. | CFO, Principal Accounting Officer & Principal Executive Officer | 635.54k | -- | 1972 |
| Ms. Julie Green M.B.A. | Chief Human Resources Officer & Head of Communications | 542.35k | -- | 1976 |
| Mr. Timothy Lee | Chief Commercial Officer | 553.87k | -- | 1974 |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer | 828.18k | -- | 1970 |
| Scott Young | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 931.68k | -- | 1973 |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Clinical Development & Medical Affairs | -- | -- | 1971 |
Invivyd, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 99
Description
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
May 15, 2025 at 12:30 PM UTC
Invivyd, Inc. Earnings Date